ERBB2 and breast carcinoma: In this study, multi‐omics profiling of breast cancer tumors from six cohorts enriched with grade III ER+HER2− patients was performed, portraying a distinctive patient subgroup that remained poorly characterized and underrepresented in previous genomic and molecular profiling studies [14, 15, 16].